About ten percent of all cases of malignant melanoma are familial cases. The genome of affected families tells scientists a lot about how the disease develops. Prof. Dr. Rajiv Kumar of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) together with Prof. Dr. Dirk Schadendorf from Essen University Hospital studied a family where 14 family members were affected by malignant melanoma.

In a genome-wide analysis of 13 metastatic prostate cancers done on men who died of metastatic prostate cancer and whose tissue samples were collected after a rapid autopsy, scientists found consistent epigenetic signatures across all metastatic tumors in each patient. 

The discovery of stable epigenetic marks that sit on the nuclear DNA of cancer cells and alter gene expression, defies a prevailing belief that the marks vary so much within each individual's widespread cancers that they have little or no value as targets for therapy or as biomarkers for treatment response and predicting disease severity. 

Studies by Ding et al (Cell 2012) revealed that telomerase dysfunction early in disease onset creates genomic aberrations crucial for telomerase-driven prostate cancer metastasis into the lumbar spine.

Live imaging technology is becoming an increasing popular tool to visualize real-time cellular events in the tumor microenvironment during metastatic progression.

McCormick Place- Chicago, IL, March 31st- April 4th 2012- was flocked with scientists across the world for the Annual American Association for Cancer Research (AACR) meeting. As with each year, the meeting featured endless plenary presentations, symposiums, as well as poster sessions and exhibitions that covered exciting advancements and technologies in the global effort to end cancer.

“Personalized medicine! What is that?”

Your question is justified. 

It was also something that Terry Procter from Peterborough, Ontario thought when he was sent a questionnaire for his opinion on the subject. He was diagnosed with prostate cancer and had his prostate removed in 2007. So, what is personalized medicine and what is the connection to cancer?

Wilms' tumors, a type of cancer typically found in the kidneys of young children, might have a new weapon against them. A new therapeutic approach that one day might be used to treat some of the more aggressive types of this disease could be possible now that  scientists have isolated cancer stem cells that lead to the growth of the tumors.

An new American Cancer Society analysis found a strong inverse association between coffee and oral/pharyngeal cancer mortality. Real coffee, not that decaffeinated stuff.

The authors say people who drank more than four cups of coffee per day were at about half the risk of death of these often fatal cancers compared to those who only occasionally or who never drank coffee.

Previous epidemiologic studies have suggested that coffee intake is associated with reduced risk of oral/pharyngeal cancer so researchers examined associations of caffeinated coffee, decaffeinated coffee, and tea intake with fatal oral/pharyngeal cancer in the Cancer Prevention Study II, a prospective U.S. cohort study begun in 1982 by the American Cancer Society.

Blocking a specific protein, ABCC10, renders tumors more vulnerable to treatment in mice

ABCC10 is a type of ATP-binding cassette drug efflux pumps, known more simply as ABC proteins. These proteins sit on the membranes of cells, where they act just like pumps—removing cancer drugs from the cell, thereby making them less effective. The body contains close to 50 such proteins but only 3 appear capable of evading the effects of cancer drugs, including common types used to treat lung, ovarian, and breast cancers.

The early results of a trial to treat leukemia with a WT1 DNA vaccine looks promising,  according to a presentation at the DNA Vaccines 2012 conference in California by Christian Ottensmeier, the trial's principal investigator and Professor of Experimental Cancer Research at the University of Southampton.

The interim results, from eight patients, are part of a phase II trial that will enroll 31 patients in its chronic myelogenous leukemia (CML) arm.  Ottensmeier

noted robust vaccine-specific antibody responses in all vaccinated patients evaluated to date. Furthermore, T cell immune responses, including those of the "killer T cells," were detected. Antibody and T cell responses are strong signals of the DNA vaccine's potential to treat the disease.